Phase 1 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older.
• People with a general health status rated as 0, 1, or 2 on a standard performance scale (meaning they are able to carry out at least some daily activities).
• People who have been confirmed by tissue testing to have small cell lung cancer (SCLC) that has not spread to other parts of the body, or who have the extensive (more widespread) form of SCLC as part of a specific sub-group in this trial.
• For the localised SCLC sub-group: people who are about to begin radiation therapy combined with chemotherapy using platinum and etoposide.
• For the extensive SCLC sub-group: people who have already completed 4 cycles of combined chemotherapy and immunotherapy (using platinum salts, etoposide, and either atezolizumab or durvalumab) as their first treatment.
• People whose cancer can be measured and assessed using standard imaging criteria (RECIST 1.1 and/or PERCIST 1.0).
• Women who could become pregnant must have a negative blood pregnancy test within 72 hours before starting the study treatment.
• Women who could become pregnant must either be surgically sterilised or agree to use two reliable methods of contraception throughout the study and for one month after the last dose of study treatment (abstinence is accepted if it is the person's usual and preferred method).
• Men whose partner or partners could become pregnant must agree to use a reliable method of contraception from the first dose of study treatment until one month after the last dose (abstinence is accepted if it is the person's usual and preferred method).
• People who are willing and able to give written consent to take part in the trial.
• People who are covered by a health insurance system.

Who may not be able to join:

• People whose cancer has spread (metastatic disease).
• People who have previously had radiation therapy to the chest, or to an area close to or overlapping with the chest radiation field planned for this trial.
• People who are unwilling or unable to give consent to participate.
• People who have a medical condition that makes chest radiation unsafe, including uncontrolled heart failure (with an ejection fraction below 30% or clinical signs), or severe breathing problems such as the most serious grade of COPD (Grade IV by GOLD classification), or certain Grade III COPD cases, or anyone with significant breathing impairment defined as dependence on oxygen, and/or lung function measurements below 40% of expected normal values (confirm with trial site).
• People who cannot take acetazolamide (the study drug) due to allergy to it, severe liver, kidney, or adrenal gland problems, intolerance to a class of medicines called sulfonamides, a history of kidney stones, or an allergy to wheat (other than coeliac disease).
• People currently taking certain other medications listed in the trial protocol (confirm with trial site).
• People with a history of another cancer, unless that cancer has been in complete remission for more than 5 years, was a fully removed skin cancer (basal cell or squamous cell), or was cervical cancer that was confined to the surface layer.
• People in certain legally protected or vulnerable categories as defined under French healthcare law, including people detained by legal or administrative decision, adults under legal guardianship or who are unable to give consent, and women who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.